Zeteo Tech, Inc.
Zeteo Tech, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Zeteo Tech, Inc..
Zeteo Tech, Inc. is a company.
Key people at Zeteo Tech, Inc..
Key people at Zeteo Tech, Inc..
Zeteo Tech, Inc. is a venture-backed biodefense and medical device company headquartered in Sykesville, Maryland, specializing in fieldable biological mass spectrometers like the patented digitalMALDI® technology.[1][2][3] It builds products that rapidly identify airborne microbes, proteins, lipids, bio-threats, and infectious diseases such as tuberculosis (TB), serving military, homeland security, veterinary, and public health sectors with cost-effective, non-invasive screening solutions.[1][2][3] Key offerings include analytical testing services, BreathBiomics for breath-based diagnosis, canine hearing protection, in-vehicle occupant detection, and the EMCAT decontamination system, addressing biosurveillance, point-of-care diagnostics, and critical infrastructure protection.[1] The company has grown revenues from $700,000 in 2014 to $3.65 million in 2019, employs around 14-25 people, and secured over $10M in Phase III SBIR/STTR funding from DoD agencies like Army CBD and DHS.[2][3]
Founded in late 2013 in Sykesville, MD, by three technology experts led by Wayne Bryden (President and CEO), Zeteo Tech emerged from Bryden's mass spectrometer research at Johns Hopkins University Applied Physics Laboratory.[3][1] The founders aimed to commercialize this work into biological detection tools for military and homeland security, while developing products to protect defenders amid rising bio-threats.[3] Early SBIR/STTR funding was pivotal, providing guidance and advancing the tech to attract venture capital from firms like Anzu Partners; the company spun off Edge Embossing at a profit and earned the 2020 Tibbetts Award for innovation.[3][2][4] Pivotal moments include DoD/DHS funding for TB screening and bio-threat detection, scaling from 3 to 14+ employees.[3]
Zeteo rides the biosurveillance and rapid diagnostics trend, amplified by pandemics like COVID-19, drug-resistant TB epidemics (no vaccine, global spread), and bio-threat proliferation.[3][4][6] Timing aligns with DoD/DHS priorities for fieldable tech amid WMD risks and critical infrastructure vulnerabilities, plus EU interest in breath analysis for health emergencies via Horizon Europe/EU4Health.[4][2] Market forces favoring Zeteo include falling mass spec costs, AI/ML integration for specificity, and demand for non-invasive, low-cost screening in high-TB regions and military ops.[1][3] It influences the ecosystem by spinning out ventures like BioFlyte (with board ties to figures like Ambassador Bolton) and enabling partners to deploy in security/pandemic scenarios, bridging defense R&D to commercial health tech.[6][7]
Zeteo is poised for expansion via BioFlyte commercialization and global TB/pandemic screening, leveraging its IP for new threats like fentanyl aerosols or resistant strains.[6][3] Trends like AI-enhanced portables, EU funding, and biotech VC growth will accelerate adoption in defense, public health, and vet med.[4][7] Influence may evolve through partnerships (e.g., DG HERA) and scale-up, potentially dominating low-cost biosurveillance as fieldable mass spec becomes standard.[1][4] This positions Zeteo as a key player in proactive bio-threat defense, echoing its origins in APL innovation.
